Laserfiche WebLink
20 <br />Laboratory Analysis Procedures <br /> <br />Reporting results <br /> <br />1 The laboratory shall report test results to Trisco System’s Medical Review Officer <br />within an average of 5 working days after receipt of the specimen by the <br />laboratory. The report shall identify the drugs/metabolites tested for, whether <br />positive or negative, the specimen number assigned by the Company (if any), and <br />the drug testing laboratory specimen identification number (accession number). <br />2 The laboratory shall report as negative all specimens that are negative on the <br />initial test or negative on the confirmatory test. Only specimens confirmed <br />positive shall be reported positive for a specific drug. <br />3 The laboratory shall send only to the Medical Review Officer the original or a <br />certified true copy of the drug testing custody and control form which, in the case <br />of a report positive for drug use, shall be signed by the individual responsible for <br />day to day management of the drug testing laboratory or the individual <br />responsible for attesting to the validity of the test reports, and attached to which <br />shall be a copy of the test report. <br />4 The laboratory shall provide to the Company an aggregate quarterly statistical <br />summary of urinalysis testing of the Company’s employee. The laboratory shall <br />provide the report to the Company not more than 14 calendar days after the end of <br />the quarter covered by the summary. Laboratory confirmation data only shall be <br />included from test results reported with that quarter. The summary shall contain <br />only the following information: (a). Number of specimens received for testing; <br />(b). Number of specimens confirmed positive for Marijuana metabolites, Cocaine <br />metabolites, Opiates, Phencyclidine, and Amphetamine; (c). Number of <br />specimens for which a test was not performed. Quarterly reports shall not contain <br />personal identifying information or other data from which it is reasonable likely <br />that information about an individual’s test can be readily inferred. If necessary, in <br />order to prevent disclosure of such data, the laboratory shall not send such a <br />report until data are sufficiently aggregated to make such an inference unlikely. <br />In any quarter in which a report is withheld for this reason, or because no testing <br />was conducted, the laboratory shall so inform the Company in writing. <br /> <br /> <br /> <br /> <br />Quality Assurance and Quality Control <br /> <br />Employer blind performance test procedures <br /> <br />1 Trisco Systems, Inc. shall use blind testing quality control procedures. <br />2 The Company shall submit 3 blind performance test specimens for each 100 <br />employee specimens it submits, up to a maximum of 100 blind performance test <br />specimens submitted per quarter. The Company shall submit only blank samples, <br />as an employer with fewer than 2000 employees.